Enzastaurin |
DLBCL in remission after R-CHOP treatment |
NCT00332202 PRELUDE |
Ongoing; not recruiting |
NA |
|
|
|
|
|
Inotuzumab ozogamicin + R versus investigator's choice of gemcitabine + R or B + R |
R/R aggressive NHL |
NCT01232556 |
Recruiting |
NA |
|
|
|
|
|
B + R versus F + R [41] |
R/R follicular, indolent, and MCL |
NCT01456351 |
Completed; final results presented at ASH 10 |
B + R had better efficacy than F + R |
B + R versus R-CHOP [42] |
Previously untreated follicular, indolent, and MCL |
NCT00991211 |
Completed; final results presented at ASH 09 |
B + R superior to R-CHOP for CR and PFS |
|
|
|
|
|
Single-agent pixantrone dimaleate versus investigator's choice therapy [49] |
Third-line treatment of R/R aggressive NHL |
NCT00088530 EXTEND (PIX301) |
Completed; final results presented at ASH 10 |
Pixantrone superior to other single-agent therapies |
Pixantrone + R versus gemcitabine + R |
R/R DLBCL patients not eligible for SCT |
NCT01321541 PIX-R (PIX306) |
Recruiting |
NA |